Thermo Fisher Scientific Inc. $TMO Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,673 shares of the medical research company’s stock after acquiring an additional 3,098 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $46,964,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. J. Stern & Co. LLP boosted its stake in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. State Street Corp grew its holdings in shares of Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after buying an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after buying an additional 26,425 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on TMO shares. Piper Sandler lifted their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Stock Down 1.1%

Shares of TMO opened at $596.65 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company’s fifty day moving average is $527.07 and its two-hundred day moving average is $509.02. The firm has a market cap of $220.61 billion, a PE ratio of 32.10, a price-to-earnings-growth ratio of 2.45 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm posted $4.28 EPS. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.